

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7735305
<b>Application Number:</b>	09993647
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1010
<b>Title of Invention:</b>	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
<b>First Named Inventor/Applicant Name:</b>	Bernd Riedl
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Caitlin Sickler
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	BAYER 18A
<b>Receipt Date:</b>	03-JUN-2010
<b>Filing Date:</b>	27-NOV-2001
<b>Time Stamp:</b>	09:42:45
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P145c-Kraft-et-al-Cancer-v85-n1-p178.pdf	1640592 5ed4b492408b63e01d1fc401c05d37b541d14bb0	no	10

### Warnings:

### Information:

2	NPL Documents	P146- KuboetalHerbicidalActivityof13 4-ThiadiazoleDerivatives.pdf	351659 4a03661079a17024730586e2ca5496cd54a 91e27	no	6
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	P147- KuboetalSynthesisandStructure activity.pdf	168474 3a3ce5677bbffaa8331f1a4d78bc9de74f1c 53cf	no	1
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	P148-KUEFER0133WO- TranslationalResearch.pdf	1583073 d845a3446bcadced870ec55cd0428c498dd 32a1a	no	10
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	P149-KUMAR-ET-AL- DrugsTargetedProteinKinases- 1.pdf	1326625 d7973ef9cb6c196a013562059fc939a6a794 b8c4	no	14
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	P150-KUPSCHETAL- ResultsSorafenibOzalipatin.pdf	112833 1525bd6428ca8446784b68413fbab4b92b5 4bcaf	no	2
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	P151-Kuriketalkyphketal.pdf	294834 280e00b40c8fb3804fe11181f8cf71849bc1 7c09	no	4
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	P152-KYRIAKISETAL- RAFActivatesMAP.pdf	608689 8d23374a15ebba96fedc919084fa798ac44 36f1	no	5
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	P152a-Laack-et-al-Annals- Oncology-v13-p1550.pdf	466032 551a02726dc75d72228a382c64d3206922c b954c	no	8
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	P153-LAGO-SelectedComb.pdf	363780 63797f89f7bbcd3626f9b4d9eb759d1b2df 1b4cd	no	15
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	P153a-LauAbrogationOfc-RafExpression.pdf	445336	no	4
			49d26870f06bcef0bd749b6cbe8470976166f611		
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	P154-LeeBayer439006BayerOnyx.pdf	589793	no	7
			79315a4885e24a64b95e2814280cb76f497a2eb8		
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	P155-LeeBicyclimidazolesAsANovelClass1993.pdf	1361567	no	22
			70278f949b0f82b9f54a8698f3a0f58f792f4a9		
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	P156-Lee-FTY7202004.pdf	4454189	no	10
			be040a2c300c6cf89c91ebc54e79e8790cab42b1		
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	P156a-Lee-et-al-European-J-Cancer-v36-p748.pdf	534393	no	6
			fe3a2473335486c3dd0788b8e5ced24658cb8712		
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	P156b-Lee-and-Heymach-Clin-Lung-Cancer-v7-n5-p304.pdf	5889811	no	5
			0fe7463c454a066ef6c2d7e607e3de3de942404c		
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	P156c-Legros-et-al-Blood-v104-n2-p495.pdf	1241512	no	7
			e19b68f75114f24aeb4b5556f09b17cb77bd13b3		
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	P157-LemoineOverviewofRasOncogenesandtheirClinicalPotential.pdf	936752	no	8
			d74909b4366d916c561b16147a926c15a4d12e49		
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	P158-LePageetalNewNaryllsoxazolecarboxamides.pdf	980785	no	13
			a9344a4c144d8ce5160e882d9e2a15e4a58b817d		
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	P159-LEUNER- Improvingdrugsolubilityfororal deliveryusingsoliddispersions. pdf	1106992  9b4bbd5e05fcd506125e4f0f9f90fcb25fff3 c4	no	14
----	---------------	---	--	----	----

**Warnings:**

**Information:**

**Total Files Size (in bytes):**

24457721

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**